
    
      This was a multicenter, randomized, rater- and dose-blinded, study to compare the efficacy
      and safety of 0.25 mg and 0.5 mg of fingolimod with glatimer acetate 20 mg s.c. in patients
      with RRMS.

      This study consisted of 3 periods:

        -  Screening Period: up to 45 days for all patients

        -  Treatment Period: 12 months of glatiramer acetate 20 mg, fingolimod 0.25 mg, or
           fingolimod 0.5 mg

        -  Follow-up occurred 3 months (12 weeks) after the last dose of study drug for all
           patients The informed consent form was signed prior to any study related activities at
           the screening visit. Randomization to either treatment group was preformed at visit 1
           after a diligent check of applicable in- and exclusion criteria in a 1:1:1 ratio
           (changed to 5:3:2 after implementation of Amendment 2 in 2015).

      Treatment groups:

        -  fingolimod 0.5 mg/day orally for up to 12 months

        -  fingolimod 0.25 mg/day orally for up to 12 months

        -  glatiramer acetate 20 mg/day subcutaneously for up to 12 months
    
  